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We read with interest the recent publication of Beer and Sahin-Tóth reporting that exonic 
variants affecting pre-mRNA splicing contribute to the genetic burden in chronic 
pancreatitis.1 One particular variant, affecting the last nucleotide of exon 3 of the SPINK1 
gene, c.194G>A, was found to cause an ~80% reduction in SPINK1 mRNA expression as 
compared to the wild-type in a minigene assay performed in human embryonic kidney 293T 
(HEK293T) cells. The SPINK1 sequence inserted into the minigene expression vector 
however comprised only exon 1, exon 2, exon 3, intron 3 and exon 4 of the four-exon gene.1 
Note that the potential effect of c.194G>A as a missense mutation (p.Arg65Gln) on protein 
function had previously been analysed; engineered expression of the full-length mutant 
coding sequence in Chinese hamster ovary cells and HEK293T cells showed consistently a 
70-80% reduction in protein secretion as compared to the wild-type.2,3 
We recently analysed the functional consequences of 24 SPINK1 intronic variants in 
relation to their associated mRNA splicing phenotypes4,5 by means of a full gene splicing 
assay in which the full-length 7 kb SPINK1 genomic sequence (including all four exons plus 
all three introns of the gene) was cloned into the pcDNA3.1/V5-His-TOPO vector.6 This full-
length gene expression system has already proved itself in practice by accurately representing 
the in vivo situation in the context of the observed splicing patterns of the SPINK1 wild-type 
gene and two pathogenic splice site variants, c.87+1G>A and c.194+2T>C.4 Naturally, a full-
length gene construct corresponds more closely to the in vivo chromosomal contexts of the 
studied genes than a minigene construct. 
We attempted to replicate the above-mentioned finding with respect to the SPINK1 
c.194G>A variant1 using our full-length splicing assay, essentially as previously described.4,5 
We introduced the c.194G>A variant into the wild-type full-length SPINK1 expression vector 
by directed mutagenesis; reverse transcription-polymerase chain reaction (RT-PCR) analyses 
of mRNAs from subsequently transfected HEK293T cells revealed a single transcript of 
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similar size to the wild-type (figure 1A); sequencing of the RT-PCR products revealed that 
the variant transcript was correctly spliced as per the wild-type. We then performed 
quantitative RT-PCR analyses of the wild-type and c.194G>A variant mRNA expressions as 
previously described,7 except that the primers used for amplifying the full-length target gene 
transcripts was changed to the primer pair Q1 as described in ref. 6. However, we failed to 
observe any significant difference between the c.194G>A variant and the wild-type in terms 
of mRNA expression (figure 1B), contrary to the results of the previous authors.1 To validate 
the performance of our quantitative RT-PCR analysis, we did two additional experiments. 
First, we demonstrated that mRNA expression of the 500 ng pcDNA3.1 plasmid harbouring 
the full-length SPINK1 genomic sequence used for quantitative RT-PCR analysis, was within 
the linear range of a transfection dosage-gene expression curve (see online supplementary 
figure S1). Second, we demonstrated that a known SPINK1 variant, c.27delC (p.Ser10fsX5) 
located in the middle of exon 1 coding sequence,8 caused a significant decreased mRNA 
expression that could be reversed by cycloheximide, a known inhibitor of nonsense-mediated 
mRNA decay7 (figure S2). 
We further assessed the likely impact of the SPINK1 c.194G>A variant in terms of the 
disruption of known splice sites and/or creation of new splice sites using the five splicing 
prediction algorithms viz. SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and 
Human Splicing Finder included within the Alamut® Visual software suite (version 2.7.1; 
Interactive Biosoftware, Rouen, France). The c.194G>A variant was predicted to have only 
slightly reduced scores as compared to the wild-type intron 3 splice donor site (see figure 
S3A). These slightly reduced scores are not suggestive of a significant impact on splicing 
based upon our current knowledge of in silico analyses.9 Moreover, the creation of a potential 
splice acceptor site was predicted by only three of the five programs; and the predicted scores 
were invariably lower than 80% of the three programs’ corresponding maximal scores (i.e., 
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70.9 of 100 for SpliceSiteFinder-like, 79.2 of 100 for Human Splice Finder and 3.7 of 16 for 
MaxEntScan; figure S3A). Further, the Alamut software suite predicted that the c.194G>A 
variant would neither affect branch-point properties (figure S3A) nor create or disrupt splicing 
regulatory elements such as exonic/intronic splicing enhancers/silencers (figure S3B). Taken 
together, the in silico analyses did not support a significant impact of the SPINK1 c.194 
variant on splicing. 
In summary, our in vitro and in silico analytical data contradict the previous report that 
the SPINK1 c.194G>A variant significantly affects pre-mRNA splicing. Consequently, we 
propose instead that the known pathogenicity of this variant is likely to be attributable to its 
impact as a missense mutation that significantly decreases protein secretion.2,3 This 
notwithstanding, it should be kept in mind that findings obtained from a model system may 
not accurately reflect in vivo situations. It is thus desirable to investigate the mRNA 
expression in the pancreatic tissue of the c.194G>A carrier.  
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Figure 1  Functional analyses of the potential impact of the SPINK1 c.194G>A variant on 
splicing using a previously described full-length gene expression assay.4,5 (A) RT-PCR 
analyses of HEK293T cells transfected with full-length gene expression constructs harbouring 
respectively the SPINK1 wild-type and c.194G>A variant sequences. (B) Relative mRNA 
expression level of the SPINK1 c.194G>A variant compared to that of the wild-type as 
determined by quantitative RT-PCR analysis of HEK293T cells transfected with the 
corresponding full-length gene expression constructs. Results are given as the mean ± SD 
from three independent transfection experiments. 
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